Tag:
Clinical Trials
Latest Headlines
Latest Headlines
Celldex scores upbeat data for breast cancer drug
The Needham, MA-based company's CDX-011 consists of an antibody targeted to the GPNMB protein and an attached chemotherapy agent that is supposed to hit tumor cells with a killer punch.
MediciNova shares crash after lead asthma drug fails IIb trial
While the CEO tried to put the data in context, offering reasons for optimism for a planned late-stage study of the lead program, investors watched the stock price crater more than 50% after the news hit.
Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement
Based on the findings published in Quintiles' annual "New Health Report," payers want to get the ball rolling sooner to get drugs approved faster.
Halo garners support for PhII DMD study
Halo wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year.
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Lilly posts clean safety data on PhIII diabetes blockbuster hopeful
Eli Lilly CEO John Lechleiter has made it clear that dulaglutide is one of the company's top blockbuster hopefuls in its late-stage pipeline.
The R&D revolution wants you
Getting to mid-stage proof of concept data on a careful budget is now one of the most demanding mandates in the industry. John Carroll will be moderating a breakfast panel on June 19 with a group of experts who will explore just how this trend is reshaping the way drugs are discovered and developed.
Home drug delivery considered a 'key initiative' for Marken
Why go to the clinical trial, when you could bring the trial home to you? Offering a home delivery service for clinical subjects is a concept supply chain service provider Marken is looking at possibly using, as an Outsourcing-Pharma story shows.
Patient recruitment should be a greater priority, drugmakers say in survey
A survey of conducted by market research firm Industry Standard Research shows that nearly 90% of surveyed drugmakers would prefer reaching patient recruitment goals at least 10% faster over cutting Phase II or Phase III trial costs 20%.
Gene IDs fast-onset Parkinson's disease
Some people with Parkinson's disease worsen more quickly, and picking out these would help physicians target early treatment and offer support to the patients and their families. A small study has pinpointed some genetic changes that could help to identify these patients and perhaps create targeted treatments.
